CA 15-3 as an alternative marker for KL-6 in fibrotic lung diseases

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 27, Issue 2, 2010, Pages 138-146

  Kruit, A ^a   Gerritsen, W B M ^a   Pot, N ^a   Grutters, J C ^a   Van Den Bosch, J M M ^a   Ruven, H J T ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Biomarkers; CA 15 3; Fibrotic lung diseases; Interstitial lung diseases; KL 6

Indexed keywords

BIOLOGICAL MARKER; CA 15-3 ANTIGEN; MUCIN; PROTEIN KL 6; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; LUNG BIOPSY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; ALVEOLITIS, EXTRINSIC ALLERGIC; BIOLOGICAL MARKERS; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MUCIN-1; ROC CURVE; YOUNG ADULT;

EID: 78651327269     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hermans C, Bernard A. Lung epithelium-specific proteins: Characteristics and potential applications as markers. Am J Respir Crit Care Med 1999; 159: 646-78. (Pubitemid 29084894)
2. Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, Surfactant Protein-A, Surfactant Protein-D, and Monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002; 165: 378-81.
3. Kohno N, Yokoyama A, Kondo K, Nakajima M. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Eur Respir J 2004; 24: A1671 (Abstract).
4. Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1988; 18: 203-16.
5. Price MR, Rye PD, Petrakou E, et al. Summary report on the isobm td-4 workshop: Analysis of 56 monoclonal antibodies against the MUC1 mucin. San diego, calif., november 17-23, 1996. Tumour Biol 1998; 19 Suppl 1: 1-20.
6. Bast RC, Jr, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer Clinical practice guidelines of the american society of clinical oncology. J Clin Oncol 2001; 19: 1865-78.
7. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989; 96: 68-73.
8. Inoue Y, Barker E, Daniloff E, Kohno N, Hiwada K, Newman LS. Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis. Am J Respir Crit Care Med 1997; 156: 109-15.
9. Ogawa Y, Ishikawa T, Ikeda K, et al. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer. Clin Cancer Res 2000; 6: 4069-72.
10. Wong RC, Klingberg S, Wilson R. Ca15-3 and cancer associated serum antigen assays are alternatives to the KL-6 assay for measuring serum muc-1 levels in patients with interstitial lung disease associated with polymyositis/dermatomyositis. J Rheumatol 2002; 29: 2021-22; author reply 2022.
11. Ricci A, Mariotta S, Bronzetti E, et al. Serum CA 15-3 is increased in pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 54-63.
12. Hunninghake GW, Costabel U, Ando M, et al. Ats/ers/wasog statement on sarcoidosis. American thoracic society/european respiratory society/world association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-73.
13. American thoracic society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American thoracic society (ats), and the european respiratory society (ers). Am J Respir Crit Care Med 2000; 161: 646-64.
14. Kohno N, Awaya Y, Oyama T, et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993; 148: 637-42.
15. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-43.
16. Okada M, Suzuki K, Nakanishi T, Nakashima M. Serum levels of KL-6 are positively correlated with those of CA15-3 in patients with interstitial pneumonia associated with collagen diseases. Respirology 2006; 11: 509-10.
17. Miyoshi S, Hamada H, Kadowaki T, et al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest 2010.
18. Janssen R, Sato H, Gratters JC, et al. Study of Clara cell 16, KL-6, and Surfactant Protein-D in serum as disease markers in pulmonary sarcoidosis. Chest 2003; 124: 2119-25.
19. Janssen R, Gratters JC, Sato H, et al. Analysis of KL-6 and SP-D as disease markers in bird fancier's lung. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: 51-7.
20. Kobayashi J, Kitamura S. Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis. Chest 1996; 109: 1276-82.
21. Irimura T, Denda K, Iida S, Takeuchi H, Kato K. Diverse glycosylation of MUC1 and MUC2: Potential significance in tumor immunity. J Biochem 1999; 126: 975-85.
22. Kim YS, Gum J, Jr, Brockhausen I. Mucin glycoproteins in neoplasia. Glycoconj J 1996; 13: 693-707.